secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001650664-26-000043
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Q1 net loss $25M ($0.26/share); EDIT-401 on track for human data by year-end
--------------------------------------------------------------------------------

- Net loss of $25.0M ($0.26 per share) vs. $76.1M ($0.92) in Q1 2025; no restructuring charges this quarter.
- Cash and equivalents $123.6M as of March 31; expected to fund operations into Q3 2027.
- R&D expenses down 34% YoY to $17.6M due to reni-cel discontinuation and headcount reduction.
- EDIT-401 preclinical shows >90% mean LDL-C reduction; first-in-human trial for HeFH expected in H2 2026 with proof-of-concept data by year-end.
- USPTO reaffirmed Broad Institute's priority in CRISPR/Cas9 patent interference, supporting Editas' licensed IP.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066426000043/0001650664-26-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066426000043/edit-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001650664-26-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer